Evidence map›Paper›PMID 30632841›Full record

Trial reportLeukemia & lymphoma2019

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis.

Prithviraj Bose, Mahesh Swaminathan, Naveen Pemmaraju, Alessandra Ferrajoli, Elias J Jabbour, Naval G Daver, Courtney D DiNardo, Yesid Alvarado, Musa Yilmaz, Julie Huynh-Lu and 8 more

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia & lymphoma, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Epigenetics-targeted drugs: current paradigms and future challenges.Signal transduction and targeted therapy · 2024
    Review
  2. Review
  3. Review
  4. Article
  5. Frontiers in cell and developmental biology · 2022
    Review
  6. Article
  7. Epigenetic Dysregulation of Myeloproliferative Neoplasms.Hematology/oncology clinics of North America · 2021
    Review
  8. Review
  9. Review
  10. Review
  11. Givinostat: an emerging treatment for polycythemia vera.Expert opinion on investigational drugs · 2020
    Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Prithviraj Bosea Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.ORCID 0000-0002-4343-5712
Mahesh Swaminathana Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Naveen Pemmarajua Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Alessandra Ferrajolia Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Elias J Jabboura Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Naval G Davera Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Courtney D DiNardoa Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Yesid Alvaradoa Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Musa Yilmaza Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Julie Huynh-Lua Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Wei Qiaob Department of Biostatistics , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Xuemei Wangb Department of Biostatistics , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Aurelio Matamorosc Division of Diagnostic Radiology , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Lingsha Zhoua Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Sherry Piercea Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Kurt D Schroedera Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Hagop M Kantarjiana Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Srdan Verstovseka Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.ORCID 0000-0002-6912-8569

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Although ruxolitinib improves symptoms and splenomegaly in patients with advanced myelofibrosis, whether this agent is truly disease-modifying remains unclear. Histone deacetylase inhibitors (HDACi) downregulate JAK2 via interference with chaperone function. Pracinostat, a pan-HDACi, has modest single-agent activity in myelofibrosis. We conducted a single-institution, phase 2, investigator-initiated trial of ruxolitinib plus pracinostat (begun after 12 weeks of ruxolitinib) in 25 patients with myelofibrosis, of whom 20 received both agents. Sixteen (80%) patients had objective responses (all 'clinical improvement'). The rate of spleen response (by palpation) was 74%, and that of symptom response 80%. Most responses occurred prior to pracinostat initiation. Three patients experienced improvement in bone marrow fibrosis, and one a near-complete molecular response after two years on study treatment. All patients discontinued pracinostat and are currently off-study. Pracinostat interruptions and dose reductions were frequent, often due to worsening anemia. These findings do not support continued development of pracinostat in myelofibrosis.

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsBenzimidazolesFemaleFollow-Up StudiesHumansMaleMiddle AgedNitrilesPrimary MyelofibrosisPrognosisPyrazolesPyrimidinesSurvival RateBenzimidazolesNitrilesPyrazolesPyrimidinesruxolitinibSB939 compoundHDAC inhibitorsJAK2 inhibitorsMyelofibrosisrational combinationstargeted therapies

Identifiers

PMID30632841
PMCPMC6594864

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.